Pfizer's Q3 sales 31%↑amid increased demand for COVID-19
By Son, Hyung Min | translator Hong, Ji Yeon
24.10.31 05:31:35
가나다라
0
Has recorded KRW 24 trillion in sales in Q3…Paxlovid·Comirnaty sales on the rise
The sales of Vyndaqel products and new anticancer drugs secured from acquiring Seagen are on the rise
The global pharmaceutical company Pfizer's sales are increasing compared to the previous year. Pfizer's growth has been driven by the sales of COVID-19 vaccines and treatments such as Paxlovid and Comirnaty.
According to industry sources on October 30, Pfizer's sales in Q3 recorded US$17.72 billion (about KRW 24.48 trillion), up 31.2% year-over-year (YoY). Pfizer's combined sales from Q1 to Q3 were US$45.864 billion (about KRW 63.47 trillion), up 2.0% from the same period last year.
Pfizer's sales growth in Q3 has been driven by COVID-19 medications. Paxlovid, a COVID-19 treatment, generated US$ 2.73 billion in Q3, up 1,238.1% YoY.
▲Sales performances of Paxlovid (dark blue) and Comirnaty (light blue) (unit: US$ 1 million) in 2023 and 2024.
The changes in the demand for COVI
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)